Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “multiple sclerosis”

Effects of Cladribine Tablets on the PK of Microgynon®Completed
NCT03745144Phase 1Updated Mar 15, 2024
Sponsor: Merck KGaA, Darmstadt, Germany
Relapsing Multiple Sclerosis (RMS)
Germany, Poland
Remote Evaluation in Patients With Multiple SclerosisUnknown
NCT06308042N/AUpdated Mar 13, 2024
Sponsor: Inonu University
Multiple Sclerosis
Observational Study of a Novel Peri Infusion Regimen on the Infusion Associated Reactions With Alemtuzumab Infusion in Patients With Multiple Sclerosis in a Canadian Clinical Setting.Completed
NCT04633967N/AUpdated Mar 13, 2024
Sponsor: Maritime Neurology
Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis
Canada
ARC Intellicare for TelerehabilitationCompleted
NCT06032468NAUpdated Mar 13, 2024
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Parkinson Disease · Multiple Sclerosis · Stroke
Italy
Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple SclerosisUnknown
NCT06303024NAUpdated Mar 12, 2024
Sponsor: Fondazione Don Carlo Gnocchi ETS
Multiple Sclerosis, Relapsing-Remitting
Italy
The Efficacy of VESPA 2.0 for Cognitive Rehabilitation in Patients With Mild Cognitive ImpairmentCompleted
NCT06281314NAUpdated Mar 8, 2024
Sponsor: IRCCS Centro Neurolesi Bonino Pulejo
Neurodegenerative Diseases · Cognitive Decline · Parkinson Disease Dementia · Alzheimer Disease
Italy
IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS StudyUnknown
NCT05417269Phase 1, Phase 2Updated Mar 8, 2024
Sponsor: Imcyse SA
Multiple Sclerosis, Relapsing-Remitting
Moldova
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompleted
NCT01412333Phase 3Updated Mar 8, 2024
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
United States, Argentina, Belarus, Belgium, Bosnia and Herzegovina +19 more
Pilates+4MS: Pilates Intervention for Multiple SclerosisCompleted
NCT06300619NAUpdated Mar 8, 2024
Sponsor: University of Colorado, Colorado Springs
Multiple Sclerosis
United States
E-Based Physical Exercise in Patients With Multiple Sclerosis and ComorbidityUnknown
NCT06298201NAUpdated Mar 7, 2024
Sponsor: University of Southern Denmark
Multiple Sclerosis
Denmark
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple SclerosisCompleted
NCT00276341Phase 3Updated Mar 7, 2024
Sponsor: Ipsen
Multiple Sclerosis, Relapsing-Remitting
France
Multi-center Database Registry to Study Thalamus Changes Using AI in MSCompleted
NCT03920995N/AUpdated Mar 6, 2024
Sponsor: University at Buffalo
Multiple Sclerosis
United States
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and BehaviourUnknown
NCT04832269N/AUpdated Mar 6, 2024
Sponsor: Jena University Hospital
Multiple Sclerosis
Germany
Biomechanical Characterization of the Locomotion in Multiple Sclerosis PatientsCompleted
NCT03756142N/AUpdated Mar 6, 2024
Sponsor: Lille Catholic University
Multiple Sclerosis
France
The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple ScelerosisUnknown
NCT06290453N/AUpdated Mar 4, 2024
Sponsor: Assiut University
Multiple Sclerosis
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to OcrelizumabCompleted
NCT04175834Phase 3Updated Mar 4, 2024
Sponsor: Providence Health & Services
Multiple Sclerosis · Infusion Reaction
United States
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisCompleted
NCT01247324Phase 3Updated Mar 4, 2024
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
United States, Argentina, Australia, Austria, Belgium +27 more
An Examination of Cognitive Fatigue Using Functional NeuroimagingUnknown
NCT04885894N/AUpdated Mar 1, 2024
Sponsor: Kessler Foundation
Multiple Sclerosis, Relapsing-Remitting
United States
The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients:Unknown
NCT06280131N/AUpdated Feb 28, 2024
Sponsor: Assiut University
Multiple Sclerosis
Teleassessment in Ataxic Multiple SclerosisCompleted
NCT05585541N/AUpdated Feb 28, 2024
Sponsor: Hacettepe University
Ataxia · Multiple Sclerosis
Turkey (Türkiye)
Online Physical Activity Tracking in Patients With Multiple SclerosisUnknown
NCT06283563NAUpdated Feb 28, 2024
Sponsor: Inonu University
Multiple Sclerosis
Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional ApproachActive Not Recruiting
NCT03198598NAUpdated Feb 28, 2024
Sponsor: Hospital Israelita Albert Einstein
Multiple Sclerosis
Brazil
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple SclerosisCompleted
NCT03396822N/AUpdated Feb 28, 2024
Sponsor: University of Maryland, Baltimore
Multiple Sclerosis
United States
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS PatientsUnknown
NCT04860947N/AUpdated Feb 26, 2024
Sponsor: Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis
France
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisTerminated
NCT03283826Phase 1, Phase 2Updated Feb 23, 2024
Sponsor: Atara Biotherapeutics
Primary Progressive Multiple Sclerosis · Secondary Progressive Multiple Sclerosis
United States, Australia, Canada

Previous page Next page